TY - JOUR
T1 - Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials
AU - Nowinski, Cindy J.
AU - Miller, Deborah M.
AU - Cella, David
N1 - Funding Information:
Acknowledgments This work was supported by funding from the National Cancer Institute, (Grant# 1U2CCA186878-01) and previously by the National Institute of Neurological Disorders and Stroke (Contract #HHSN271201200036C).
Publisher Copyright:
© 2017, The American Society for Experimental NeuroTherapeutics, Inc.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Patient-reported outcomes (PROs) are playing an increasing role in multiple sclerosis (MS) research and practice, and are essential for understanding the effects that MS and MS treatments have on patients’ lives. PROs are captured directly from patients and include symptoms, function, health status, and health-related quality of life. In this article, we review different categories (e.g., generic, targeted, preference-based) of PRO measures and considerations in selecting a measure. The PROs included in MS clinical research have evolved over time, as have the measures used to assess them. We describe findings from recent MS clinical trials that included PROs when evaluating Food and Drug Administration-approved disease-modifying therapies (e.g., daclizumab, teriflunomide). Variation in the measures used in these trials makes it difficult to draw any conclusions from the data. We therefore suggest a standardized approach to PRO assessment in MS research and describe 2 generic, National Institutes of Health-supported measurement systems [Neuro-QoL and the Patient-Reported Outcomes Measurement Information System (PROMIS)] that would facilitate such an approach. The use of PROs in MS care and research is expanding beyond clinical trials, as is demonstrated by examples from comparative effectiveness and other patient-centered research. The importance of PRO assessment is expected to continue to grow in the future.
AB - Patient-reported outcomes (PROs) are playing an increasing role in multiple sclerosis (MS) research and practice, and are essential for understanding the effects that MS and MS treatments have on patients’ lives. PROs are captured directly from patients and include symptoms, function, health status, and health-related quality of life. In this article, we review different categories (e.g., generic, targeted, preference-based) of PRO measures and considerations in selecting a measure. The PROs included in MS clinical research have evolved over time, as have the measures used to assess them. We describe findings from recent MS clinical trials that included PROs when evaluating Food and Drug Administration-approved disease-modifying therapies (e.g., daclizumab, teriflunomide). Variation in the measures used in these trials makes it difficult to draw any conclusions from the data. We therefore suggest a standardized approach to PRO assessment in MS research and describe 2 generic, National Institutes of Health-supported measurement systems [Neuro-QoL and the Patient-Reported Outcomes Measurement Information System (PROMIS)] that would facilitate such an approach. The use of PROs in MS care and research is expanding beyond clinical trials, as is demonstrated by examples from comparative effectiveness and other patient-centered research. The importance of PRO assessment is expected to continue to grow in the future.
KW - Clinical trials
KW - Health-related quality of life
KW - Multiple sclerosis
KW - Patient-reported outcomes
UR - http://www.scopus.com/inward/record.url?scp=85029517030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029517030&partnerID=8YFLogxK
U2 - 10.1007/s13311-017-0571-6
DO - 10.1007/s13311-017-0571-6
M3 - Review article
C2 - 28913785
AN - SCOPUS:85029517030
VL - 14
SP - 934
EP - 944
JO - Neurotherapeutics
JF - Neurotherapeutics
SN - 1933-7213
IS - 4
ER -